The usual abemaciclib starting dose is 150 mg twice daily; a lower dose or altered schedule may be prescribed. Abemaciclib is taken twice daily continuously for up to two years with endocrine therapy, unless recurrence or unacceptable toxicity requires an earlier change. A four-week dispensing block is not a rest cycle. Endocrine treatment normally continues beyond abemaciclib.
Continuous oral treatmentFor eligible high-risk node-positive early breast cancer, adding abemaciclib to endocrine therapy reduces the risk of recurrence after surgery.
Abemaciclib inhibits CDK4 and CDK6 proteins. These proteins help cells move towards division. It is combined with endocrine treatment to reduce recurrence risk in eligible high-risk early breast cancer.
Start the prescribed diarrhoea rescue plan at the first loose stool and contact the team. Breathlessness, a swollen painful leg, fever or jaundice need prompt assessment.
The chosen endocrine medicine either reduces oestrogen production or blocks its action. An aromatase inhibitor may need ovarian suppression before menopause. The exact drug and duration are prescribed separately.
Tell the team about joint pain, hot flushes, vaginal symptoms and mood changes. The bone-health and clot-risk discussion depends on the drug chosen.
This is a visual orientation, not a prediction of your personal cycle. It shows when some effects often emerge and which effects are not tied to a particular day.
The usual abemaciclib starting dose is 150 mg twice daily; a lower dose or altered schedule may be prescribed. Abemaciclib is taken twice daily continuously for up to two years with endocrine therapy, unless recurrence or unacceptable toxicity requires an earlier change. A four-week dispensing block is not a rest cycle. Endocrine treatment normally continues beyond abemaciclib.
There are no guaranteed “safe days”. Fever, shivers or suddenly feeling unwell require immediate contact. Serious symptoms override the timeline or diary.
Columns show sequence and general intervals, not equal periods or booked appointments. The team confirms who arranges each test, who reviews results and who authorises treatment or restart.
| Check | Before first dose | First two months | Next two months | Later treatment | Two-year completion / change |
|---|---|---|---|---|---|
| Abemaciclib and endocrine partner | Confirm high-risk eligibility and treatment timing | Twice daily continuously; no rest week | Continue if tolerated | Up to two years; endocrine treatment continues | Review endocrine plan separately |
| FBC / renal / liver / bone profile | Baseline blood tests | Every two weeks | Monthly | As clinically indicated | Follow unresolved abnormalities |
| ECG / heart rhythm | As clinically indicated | Repeat if clinically indicated | No routine Day-14 ECG schedule | Symptoms/risk guide testing | Follow any identified problem |
| Diarrhoea / hydration | Rescue medicine and contact plan ready | Start action plan at first loose stool | Continue symptom and intake review | Contact team between visits for persistent symptoms | Follow recovery; do not self-restart held doses |
| Clots / lungs / infection | Review prior VTE and breathing symptoms | Prompt assessment of warning symptoms | Continue symptom review | Report new leg swelling, chest or breathing symptoms | Symptoms still need assessment after stopping |
| Bone / endocrine / follow-up | Assess fracture risk; confirm AI/OFS or other partner | Support hormone-related symptoms | Continue endocrine and bone plan | Early-breast surveillance and risk-based bone review | Endocrine treatment and surveillance continue |
HR-positive / HER2-negative early breast cancer · adjuvant
The usual abemaciclib starting dose is 150 mg twice daily; a lower dose or altered schedule may be prescribed. Abemaciclib is taken twice daily continuously for up to two years with endocrine therapy, unless recurrence or unacceptable toxicity requires an earlier change. A four-week dispensing block is not a rest cycle. Endocrine treatment normally continues beyond abemaciclib.
On a small screen, swipe the map sideways. The checks below give the same timing in words.
| Care / check | Before first dose | First two months | Next two months | Later treatment | Two-year completion / change |
|---|---|---|---|---|---|
| Abemaciclib and endocrine partnerNCCP 00619 · SMPC | Confirm high-risk eligibility and treatment timing | Twice daily continuously; no rest week | Continue if tolerated | Up to two years; endocrine treatment continues | Review endocrine plan separately |
| FBC / renal / liver / bone profileNCCP 00619 · SMPC | Baseline blood tests | Every two weeks | Monthly | As clinically indicated | Follow unresolved abnormalities |
| ECG / heart rhythmNCCP 00619 · SMPC | As clinically indicated | Repeat if clinically indicated | No routine Day-14 ECG schedule | Symptoms/risk guide testing | Follow any identified problem |
| Diarrhoea / hydrationNCCP 00619 · SMPC | Rescue medicine and contact plan ready | Start action plan at first loose stool | Continue symptom and intake review | Contact team between visits for persistent symptoms | Follow recovery; do not self-restart held doses |
| Clots / lungs / infectionNCCP 00619 · SMPC | Review prior VTE and breathing symptoms | Prompt assessment of warning symptoms | Continue symptom review | Report new leg swelling, chest or breathing symptoms | Symptoms still need assessment after stopping |
| Bone / endocrine / follow-upNCCP 00619 · SMPC | Assess fracture risk; confirm AI/OFS or other partner | Support hormone-related symptoms | Continue endocrine and bone plan | Early-breast surveillance and risk-based bone review | Endocrine treatment and surveillance continue |
Check eligibility, organ function and the exact treatment/support plan.
Ask / act: Confirm who arranges each check and who reviews it.
Sources: NCCP 00619 · SMPC
Important toxicity can begin before the first routine review.
Ask / act: Keep early appointments and use the agreed symptom-contact plan.
Sources: NCCP 00619 · SMPC
Longer-term treatment still needs clinical review.
Ask / act: Ask about symptom support, results and the next decision.
Sources: NCCP 00619 · SMPC
The targeted medicine and endocrine partner may have different stop dates.
Ask / act: Confirm each medicine and the ongoing follow-up plan.
Sources: NCCP 00619
This map does not show whether a test has been ordered, booked or completed. Do not wait for a scheduled test if you develop new symptoms.
For eligible high-risk node-positive early breast cancer, adding abemaciclib to endocrine therapy reduces the risk of recurrence after surgery.
HR-positive/HER2-negative node-positive early breast cancer at high recurrence risk: four or more positive axillary nodes, or one to three with tumour at least 5 cm and/or grade 3. The NCCP timing, prior-treatment and other exclusions remain applicable; this is not a node-negative or metastatic regimen.
The usual abemaciclib starting dose is 150 mg twice daily; a lower dose or altered schedule may be prescribed. Abemaciclib is taken twice daily continuously for up to two years with endocrine therapy, unless recurrence or unacceptable toxicity requires an earlier change. A four-week dispensing block is not a rest cycle. Endocrine treatment normally continues beyond abemaciclib. At completion of the planned two-year abemaciclib course, continue the separately agreed endocrine and follow-up plan.
Baseline tests and ongoing tests have different purposes.
FBC, renal, liver and bone profile; ECG as clinically indicated. Confirm node-positive high-risk eligibility, definitive surgery and timing: within 16 months of resection and up to 12 weeks of endocrine treatment after the last non-endocrine treatment before starting. Assess VTE history, bowel function, all medicines, endocrine partner, ovarian suppression if using an AI before menopause, and bone/reproductive health.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
FBC, renal, liver and bone profile every two weeks for the first two months, monthly for the next two months, then as clinically indicated. More frequent liver monitoring for grade 2 or worse liver abnormalities. ECG is driven by clinical need; no routine ribociclib Day-14 ECG schedule. Early and ongoing diarrhoea review, hydration/intake, infection, clots, breathlessness and adherence; prompt action between appointments. Creatinine can rise through inhibited tubular secretion without a true fall in filtration; assess the clinical context and alternative renal measures if needed.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
Supportive medicines and the endocrine partner have their own plan.
Have the prescribed antidiarrhoeal treatment available before starting. Begin the agreed plan at the first loose stool, increase fluids as advised and contact the team early; persistent symptoms or dehydration may require a treatment hold.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
NCCP classifies abemaciclib as oral moderate–high emetic risk. Agree preventive or rescue antiemetics using individual risk and local oral-SACT policy.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
Attend early two-weekly then monthly checks even when tablets are taken at home. Seek prompt advice for infection, jaundice, new breathing symptoms or possible blood clots.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
Discuss symptoms and bone protection for the actual endocrine partner. Ovarian suppression is required with an AI before menopause. Endocrine treatment normally continues after the two-year abemaciclib course.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
Take tablets whole at the prescribed regular times. There is no routine week off. Check grapefruit/CYP3A interactions and do not double a missed or vomited dose.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
Adding a planned course of abemaciclib to endocrine therapy reduced the chance of invasive cancer returning in eligible high-risk, node-positive early breast cancer. Longer follow-up also showed an overall-survival benefit. These group results do not predict your own outcome.
Study results describe groups with defined treatment and eligibility. Ask about your own likely benefits, important harms, alternatives and remaining uncertainty.
monarchE primary OS and seven-year outcomes, Johnston et al; online 2025, Annals of Oncology 2026
At completion of the planned two-year abemaciclib course, continue the separately agreed endocrine and follow-up plan.
The team confirms the plan for each medicine and the next review. Do not restart a clinically held treatment from this educational timeline.
NCCP 00619 v4a · official regimen · EMA Verzenios current product information; checked 2026-10-25
Have the prescribed antidiarrhoeal treatment available before starting. Begin the agreed plan at the first loose stool, increase fluids as advised and contact the team early; persistent symptoms or dehydration may require a treatment hold.
NCCP classifies abemaciclib as oral moderate–high emetic risk. Agree preventive or rescue antiemetics using individual risk and local oral-SACT policy.
Attend early two-weekly then monthly checks even when tablets are taken at home. Seek prompt advice for infection, jaundice, new breathing symptoms or possible blood clots.
Discuss symptoms and bone protection for the actual endocrine partner. Ovarian suppression is required with an AI before menopause. Endocrine treatment normally continues after the two-year abemaciclib course.
Take tablets whole at the prescribed regular times. There is no routine week off. Check grapefruit/CYP3A interactions and do not double a missed or vomited dose.
Studies describe groups. Ask how closely the treatment and study population match your situation.
Your team can discuss the strength and limitations of the evidence alongside treatment risks and alternatives.
Acute Oncology Service
Ask for medical oncology
Other hospitals: use the contacts your own team provides.
The usual abemaciclib starting dose is 150 mg twice daily; a lower dose or altered schedule may be prescribed. Abemaciclib is taken twice daily continuously for up to two years with endocrine therapy, unless recurrence or unacceptable toxicity requires an earlier change. A four-week dispensing block is not a rest cycle. Endocrine treatment normally continues beyond abemaciclib. At completion of the planned two-year abemaciclib course, continue the separately agreed endocrine and follow-up plan.
FBC, renal, liver and bone profile; ECG as clinically indicated. Confirm node-positive high-risk eligibility, definitive surgery and timing: within 16 months of resection and up to 12 weeks of endocrine treatment after the last non-endocrine treatment before starting. Assess VTE history, bowel function, all medicines, endocrine partner, ovarian suppression if using an AI before menopause, and bone/reproductive health. FBC, renal, liver and bone profile every two weeks for the first two months, monthly for the next two months, then as clinically indicated. More frequent liver monitoring for grade 2 or worse liver abnormalities. ECG is driven by clinical need; no routine ribociclib Day-14 ECG schedule. Early and ongoing diarrhoea review, hydration/intake, infection, clots, breathlessness and adherence; prompt action between appointments. Creatinine can rise through inhibited tubular secretion without a true fall in filtration; assess the clinical context and alternative renal measures if needed.
No. This map shows general timing without personal information. Your hospital arranges actual appointments; ask who books each test and who reviews its result.
Take abemaciclib twice daily at regular times with or without food. Swallow whole; do not split, chew or crush. Avoid grapefruit. Do not replace a missed or vomited dose. A clinical hold and restart require the treating team’s instructions. A hold may affect one medicine rather than the whole combination; confirm each component.
Adding a planned course of abemaciclib to endocrine therapy reduced the chance of invasive cancer returning in eligible high-risk, node-positive early breast cancer. Longer follow-up also showed an overall-survival benefit. These group results do not predict your own outcome.
At completion of the planned two-year abemaciclib course, continue the separately agreed endocrine and follow-up plan. Keep the separately agreed disease follow-up, endocrine and bone-health plan.
Explain the plan back: Which medicine is taken when, which test is due next, who reviews it, and which symptoms mean you should call today?
The NCCP regimen supplies the treatment rules. Separate guidelines supply the longer-term monitoring recommendations, with their qualifications retained.
Source reconciled; independent clinical, pharmacy and patient/PPI review pending